Avutometinib Plus Defactinib Shows High Response Rates in Heavily Treated LGSOC
Avutometinib plus defactinib led to tumor regression in most heavily pretreated patients with recurrent low-grade serous ovarian cancer.
Avutometinib plus defactinib led to tumor regression in most heavily pretreated patients with recurrent low-grade serous ovarian cancer.
TAR-200 displayed a high complete response rate in Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer.
James Allison, Ph.D., is co-leader of the Immunotherapy Moon Shot platform at MD Anderson Cancer Center. He was recently named one of TIME’s 100 most…
A real-world study found adding a PD-L1 inhibitor to cabozantinib offered no significant survival advantage for patients with metastatic kidney cancer who had already received…
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
Nature Reviews Disease Primers – This Primer by Weller and colleagues summarizes the epidemiology, pathophysiology, diagnosis and treatment of glioma in both adults and children.
Prostate cancer is the most common type of cancer in men and is currently the second-leading cause of death in men in the U.S. In…
Hana Safah, MD, and Corey Cutler, MD, MPH, conclude with clinical insights on addressing medication access and the supportive care needs of patients with GvHD.
Monica Avila, MD, talks about what inspires her, what challenges her and what exciting projects she’s working on
Mohamad Mohty, MD, PhD, highlights key takeaways from the 50th Annual EMBT Meeting, focusing on ongoing efforts within the GVHD treatment arena.
Lung and Bronchus Cancer statistics